• SENSEX
    NIFTY 50
Healthcare

Why Glenmark Pharmaceuticals is on a deal spree

Updated : August 17, 2018 01:53 PM IST

Glenmark on July 6th announced an exclusive licensing agreement with Australian company Seqirus for one of its drug under development Ryaltris or GSP 301.
A month later after the Ryaltris deal, Glenmark announced an exclusive licensing agreement for its oncology molecule under development- GBR 1302.
The third deal announced by Glenmark was with its Q1FY19 numbers on 10th of August, just a few days after the agreement on Ryaltris.
Why Glenmark Pharmaceuticals is on a deal spree

You May Also Like

Live TV

recommended for you

Advertisement